fbpx
CAS Insight

molecules of the month

GCC5694A

oral SGLT2 inhibitor

Clinical candidate for diabetes

from literature SGLT2 inhibitor

Bioorganic Med. Chem. Lett.

GC Pharma (Green Cross)

oral SGLT2 inhibitor - GC Pharma (Green Cross)
2 mins read

Context. GCC5694A (GC Pharma (Green Cross)) is an oral SGLT2 inhibitor. SGLT2 inhibitors help glycemic control in diabetes by preventing reabsorption of glucose in the kidney. Dapagliflozin was the first SGLT2 inhibitor approved in the EU (2012), and canagliflozin was the first to be approved in the US (2013). We recently highlighted remogliflozin, an SGLT1-sparing drug launched in India in 2019 with a unique origin, and a Janssen dual SGLT1/2 inhibitor based on the natural product phlorizin. There are now eight gliflozins approved for clinical use worldwide. GCC5694A is reported to be in clinical trials in South Korea, though it is not in GC Pharma’s pipeline.Though it is not clear from the data presented how GCC5694A differentiates from previous SGLT2…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: